MGV354 is a soluble activator of guanylate cyclase(sGC) with EC 50 s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively [1] [2].

Treatment with MGV354, ranging from 0.1 nM to 10 μM, for one hour induces a dose-dependent elevation in cGMP levels within normal human trabecular meshwork (NTM) cells, showcasing an average effective concentration (EC50) of 2.5±1.6 nM after ODQ (20 μM) administration. The resultant average cGMP concentration achieved by MGV354 in NTM cells is 46±28 nM. Moreover, at a concentration of 1 μM, MGV354 consistently augments intracellular cGMP levels in NTM cells in a linear, time-dependent fashion, under assay conditions extending up to three hours [3].

MGV354 (Compound (+)-23) significantly reduces intraocular pressure in a cynomolgus model with elevated pressure for 24 hours following a single topical ocular drop and has been advanced for clinical evaluation [1].